Timber pharmaceuticals announces last patient last visit in phase 2b control study evaluating tmb-001 in moderate to severe congenital ichthyosis

- topline results expected to be announced in the fourth quarter of 2021 -
TMBR Ratings Summary
TMBR Quant Ranking